MicroMass President Jay Bigelow Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Lif... (t

(Date:12/3/2009)... Inverness Medical Innovations, Inc. (NYSE: IMA ), a ... health at home through the merger of rapid diagnostics and ... on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). ... stock in an amount per share equal to the quotient ...

(Date:12/2/2009)... announces that a new market research report ... Neurostimulation - A Global Market Perspective ... world neurostimulation market stands enthused by the ... resultant rise in age-related diseases such as, ...

(Date:12/2/2009)... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... and dosimetry trial of Cotara® in patients with relapsed ... Cotara is a targeted monoclonal antibody linked to ... for GBM. Cotara specifically targets cells at the ...

(Date:12/2/2009)... December 2 Gamida Cell announced today,a feasibility ... of a gene therapy product which combines technology ... product may have potential to,treat inherited anemias such ... Gamida Cell is developing a series of technologies ...

Breaking Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2 Reportlinker Adds Neurostimulation - A Global Market Perspective 3 Reportlinker Adds Neurostimulation - A Global Market Perspective 4 Reportlinker Adds Neurostimulation - A Global Market Perspective 5 Reportlinker Adds Neurostimulation - A Global Market Perspective 6 Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2 Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3 Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4 Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5 Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2 Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3

[0] Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock [0] Reportlinker Adds Neurostimulation - A Global Market Perspective [0] Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial [0] Gamida Cell Announces Feasibility Study With Weill Cornell Medical College

... Although Madison has made a deal with Georgia-based Cellnet ... not be an overnight event. Certain areas will be initially ... Square expected to be approved by the City Council in ... of Madison has taken an active role in brokering Cellnets ...

... At Third Wave Technologies, former vice president Kevin Conroy ... Puisis, who was CEO since mid-2004 and previously held other ... to Third Wave and stayed for a specific purpose," Puisis ... an upgraded, highly-skilled management team in place, that purpose has ...

... Third Wave Technologies ' compensation in a patent lawsuit ... legal fees. Stratagene is proceeding with its appeal. , ... found that Stratagene willfully infringed on two patents covering ... million. , ,Third Wave uses the technology in its ...

Other Biology Technology:Madison wireless deal goes forward with Cellnet 2

Madison wireless deal goes forward with Cellnet Third Wave CEO steps aside as company departs research market Third Wave wins triple damages in patent case

(Date:12/3/2009)... Now in its 32nd year, the CTRC-AACR San ... in breast cancer science and world leaders from industry ... , This year, more than 8,500 scientists and ... Convention Center in San Antonio from Dec. 9-13, 2009. ...

(Date:12/3/2009)... the design of the upcoming forest deal at Copenhagen in ... at the University of Leeds. , Writing today in ... 50% of the carbon credit payments to be agreed at ... should be made to forest dwellers directly, and their property ...

(Date:12/2/2009)... an increased risk of developing lung cancer in adulthood, even ... are published in Cancer Epidemiology, Biomarkers & Prevention , ... part of a special tobacco focus in the December issue. ... be diagnosed with lung cancer; more than 159,000 will die ...

Breaking Biology News(10 mins):CTRC-AACR San Antonio Breast Cancer Symposium continues to expand 2 Forest deal at Copenhagen must avoid creating 'carbon refugees' 2 Secondhand smoke exposure in childhood increases lung cancer risk later in life 2 Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 1 Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 2 Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 3 Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 4 Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 5 Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 6 Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4703 7 Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 1 Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 2 Cord Blood America Leases Las Vegas Building for Its Own Stem Cell Laboratory 51174 3 Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 1 Big Cuts in Family Budgets Usually Means Insurance Gets the Ax 51171 2

[0] CTRC-AACR San Antonio Breast Cancer Symposium continues to expand [0] Forest deal at Copenhagen must avoid creating 'carbon refugees'[0] Secondhand smoke exposure in childhood increases lung cancer risk later in life

... (IL-2), an immune-boosting drug used experimentally in HIV therapy, ... system T cells in some HIV-positive people who respond ... of Health (NIH) Clinical Center and the National Institute ... NIH. A report describing the study, led by the ...

... heart attack and unstable angina patients placed on beta-blocker ... to a study by researchers at Washington University School ... Heart Institute in Kansas City. The study appears in ... the American Medical Association. , "In our investigation of ...

... of 72 cases of monkeypox in the United States ... fatality, even though the disease usually kills 10 percent ... patients die? New research from Saint Louis University Health ... answer. , In this month's issue of Virology, researcher ...

Other Biology News:HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 2 HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find 3 Survival of heart patients on beta-blockers varies greatly with genetic variation 2 Survival of heart patients on beta-blockers varies greatly with genetic variation 3 Survival of heart patients on beta-blockers varies greatly with genetic variation 4 Monkeypox mystery: New research may explain why 2003 outbreak in the US wasn't deadly 2

HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find Survival of heart patients on beta-blockers varies greatly with genetic variation Monkeypox mystery: New research may explain why 2003 outbreak in the US wasn't deadly

Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...

Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...

Umbilical cord blood mononuclear cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...

Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...

Biology Products:

PBMC Cell Chip-IHC from 3H Biomedical AB B Cell Chip-IHC from 3H Biomedical AB UCB MNC Cell Chip-IHC from 3H Biomedical AB PDC Cell Chip-IHC from 3H Biomedical AB

MicroMass President Jay Bigelow Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Lif...(t _new http://www.micromass.com . CO...)